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Abstract
Background: Two-stage exchange arthroplasty is still the preferred treatment choice for chronic PJI. However, the
results remain unpredictable. We analyzed the treatment success of patients with an infected hip prosthesis, who
were treated according to a standardized algorithm with a multidisciplinary team approach and evaluated with a
strict definition of failure.
Methods: In this single-center prospective cohort study, all hip PJI episodes from March 2013 to May 2015 were
included. Treatment failure was assessed according to the Delphi-based consensus definition. The Kaplan-Meier
survival method was used to estimate the probability of infection-free survival. Patients were dichotomized into two
groups depending on the number of previous septic revisions, duration of prosthesis-free interval, positive culture
with difficult-to-treat microorganisms, microbiology at explantation, and microbiology at reimplantation.
Results: Eighty-four patients with hip PJI were the subject of this study. The most common isolated microorganisms
were coagulase-negative staphylococci (CNS) followed by Staphylococcus aureus and Propionibacterium. Almost half of
the study cohort (46%) had at least one previous septic revision before admission. The Kaplan-Meier estimated
infection-free survival after 3 years was 89.3% (95% CI, 80% to 94%) with 30 patients at risk. The mean follow-up
was 33.1 months (range, 24–48 months) with successful treatment of PJI. There were no statistical differences in
infect eradication rate among the dichotomized groups.
Conclusions: High infect eradication rates were achieved in a challenging cohort using a standardized two-stage
exchange supported by a multidisciplinary approach.
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Introduction
Periprosthetic joint infection (PJI) is a serious and challen-
ging complication following total hip arthroplasty (THA).
Despite developments in preventative medicine and iden-
tification of multiple risk factors, the incidence of PJI is
still around 1% following primary THA [1]. With the
growing numbers of THA each year [2, 3], the total num-
ber of PJI is also rising, with nearly 52,000 registered
revisions for hip PJI in the USA performed between
January 1, 2009, and December 31, 2013 [2]. Although the
best treatment option of PJI is unclear, two-stage exchange
arthroplasty is still the preferred treatment choice for
chronic PJI [4] associated with high eradication rates
around 90% [5–7]. However, results remain unpredictable
and some recent studies are showing failure rates of > 20%
with a strict definition of success [8–10]. Furthermore,
there is still no consensus about the optimal treatment
concept in a two-stage exchange arthroplasty. The most
controversial aspects are optimal duration of antibiotic
therapy, optimal length of prosthesis-free interval, timing
of reimplantation, antibiotic-free period and aspiration
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prior reimplantation, and the role of reimplantation
microbiology [8, 11]. The purpose of this study was to re-
port the outcome of our two-stage revision protocol, in
which a multi-disciplinary team guides the management
of all patients, and all diagnostic and treatment processes
are based on a standardized algorithm.
Methods
Study design and population
In this single-center prospectively followed cohort study,
all hip PJI episodes from 2013 to 2015 were included,
which were treated by a standardized comprehensive
diagnostic and therapeutic algorithm with two-stage ex-
change. Native infected joints, joints with missing data,
joints with mega prostheses, and patients with a
follow-up period less than 24 months were excluded.
The study protocol was reviewed and approved by the
institutional ethics committee (EA4/040/14).
Data collection
On admission, age, gender, comorbidities, history of the
infected joint, the score of the Charlson comorbidity
index (CCI) [12], laboratory values such as serum
C-reactive protein (CRP) and blood leukocytes, and
presumed route of infection (intraoperative versus
hematogenous) were recorded. In addition, the following
data were extracted: number of revision surgeries be-
tween stages, length of hospital stay, total duration of
antimicrobial therapy, serum CRP value at the time of
reimplantation, and microbiological and pathological re-
sults of revisions and reimplantation.
Definitions
In this cohort, PJI was diagnosed according to proposed
European Bone and Joint Infection Society (EBJIS) criteria
[13], since these criteria were used in several outcome
studies [14–16]. The definition for successfully treated PJI
was based on the Delphi-based international multidiscip-
linary consensus [17] and was further modified; treatment
was considered as successful, if all of the following criteria
were fulfilled at the latest follow-up: (i) infection eradica-
tion, characterized by a healed wound without fistula,
drainage, or pain, and no recurrence of the infection
caused by the same organism; (ii) no subsequent surgical
intervention for persistent or perioperative infection after
reimplantation surgery; (iii) no occurrence of PJI related
mortality; and (iv) no long-term (> 6months) antimicro-
bial suppression therapy.
Microorganisms such as rifampin-resistant staphylo-
cocci, enterococci, ciprofloxacin-resistant gram-negative
bacteria, and fungi were defined as difficult-to-treat
(DTT) due to the absence of available antibiofilm-active
treatment [18].
Diagnostic algorithm
Each patient underwent a standardized comprehensive
diagnostic algorithm. All patients were evaluated by a
thorough physical examination with respect to the clin-
ical patient status and soft tissue conditions. Laboratory
tests were performed including C-reactive protein
(CRP), and plain anteroposterior and lateral radiographs
were made. All patients with suspected PJI underwent a
diagnostic arthrocentesis. The synovial fluid analysis in-
cluded total cell count, differential leukocyte count,
culture for aerobic and anaerobic organisms, and histo-
logical analysis. A synovial fluid leukocyte count of more
than 2000/mm3 or a finding with more than 70% neu-
trophils was our cutoff value for the diagnosis of PJI
[18]. A positive histopathology was defined as a mean of
≥ 23 granulocytes per ten high-power fields, correspond-
ing to type 2 or type 3 periprosthetic membrane [19]. In
case of a dry tap, patients with chronic painful prosthesis
underwent a diagnostic surgery to gain at least five peri-
prosthetic tissue samples for microbiological and histo-
pathological analysis or a diagnostic explantation when
the suspicion of infection was very high. The cultures
were always incubated for 14 days. In case of fever or
systemic infection signs, blood cultures for aerobic and
anaerobic organisms were obtained and an intensive
search for potential primary focus of infection, such as
infectious endocarditis, dental (periodontitis, periapical
dental abscess, or dental intervention), urogenital, and
gastrointestinal source, was done. The explanted pros-
thesis was sent to sonication to increase the accuracy of
microbiologic diagnosis [20].
Surgical and antimicrobial treatment
The first stage consisted of removal of all implants, as
well as infected and necrotic tissue, bone cement, and
all other foreign material with a following irrigation and
debridement of the surrounding tissues. In most epi-
sodes, a cement spacer was not routinely used, unless
dead space management or the fixation of a proximal
femur fracture was necessary.
Antibiotic treatment was started intravenously (IV)
after taking multiple tissue samples during the explant-
ation or in the case of patients presenting with sepsis
preoperatively after synovial aspiration. Each patient
underwent a standardized antimicrobial therapy, which
was based on a previously published concept [18] under
the surveillance of our infectious disease specialists [21].
IV treatment was continued for the first 2 weeks after
surgery and followed by an oral regimen, if possible. In
case of a persistent infection (discharging wound and/or
increasing CRP without any other focus and/or local
signs of infection), an irrigation and debridement (and
spacer exchange, if applicable) of the explanted hip joint
was performed. All patients received antibiotics until
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reimplantation surgery without an antibiotic-free period
and diagnostic aspiration. A reimplantation was per-
formed, when the wound was healed, soft tissues were
ready for surgery, the general status of the patient was
suitable, and there was no clinical sign of a persisting
infection. If DTT microorganisms were isolated, a lon-
ger prosthesis-free interval (> 6 weeks) was preferred
[22]. The reimplantation was used in every patient as
another opportunity to perform one more thorough de-
bridement of the surrounding soft tissues and bone
prior to placement of the definitive components. Dur-
ing each explantation and reimplantation, at least five
periprosthetic tissue samples were collected for micro-
biological analysis. After reimplantation, antibiotics
were administered for 2 weeks via the intravenous route
followed by an oral biofilm-active (in non-DTT PJI) or
non-biofilm-active antimicrobial treatment (in DTT
PJI) for a total treatment duration of at least 12 weeks
with a minimum of 6 weeks’ antimicrobial course after
reimplantation.
A therapy with biofilm-active antibiotics, such as ri-
fampin or fluoroquinolones, was started only after reim-
plantation, when all drains were removed, the wound
was dry, and the bacterial load was reduced by initial
antimicrobial therapy not to cause the emergence of re-
sistance [23, 24]. If medically stable, patients received
antimicrobial therapy at home through a peripherally
inserted central catheter (PICC) line, when oral anti-
microbial therapy was not possible due to multiple drug
resistance.
In case of a relevant positive culture during reim-
plantation (≥ 2 samples were positive for the same
microorganism), or a polymicrobial infection (or if
the isolated microorganism was the same as the initial
infecting organism even if only one culture was posi-
tive), antimicrobial therapy was continued for 12
weeks after reimplantation. Otherwise, the standard
therapy was given for 6 weeks after reimplantation as
planned. A chronic antibiotic suppression was used
for patients with increased risk of relapse, including a
history of multiple joint infections, deficient immune
system, and comorbidities predisposing to PJI [25],
after individualized decision-making through a multi-
disciplinary team, including infectious disease special-
ists, internal medicine specialists, and orthopedic
surgeons, who were involved in every stage of PJI
management for each patient.
Outcome analysis
Patients were seen in the outpatient clinic after 3, 6, and
12months and after that period annually. Clinical, labora-
tory, and radiological evaluation were performed by an
orthopedic surgeon and an infectious disease specialist.
Statistical analysis
Patients were dichotomized into two groups depend-
ing on the number of previous septic revisions (no
previous septic revision vs. ≥ 1 previous septic revi-
sion), duration of prosthesis-free interval (short < 6
weeks vs. long > 6 weeks), positive culture with DTT
microorganisms (DTT vs. non-DTT), microbiology at
explantation (polymicrobial vs. monomicrobial), and
microbiology at reimplantation (positive vs. negative).
A two-tailed Fisher’s exact test was employed to find
significant differences between dichotomized groups.
The probability of infection-free survival and the re-
spective 95% confidence interval (95% CI) was esti-
mated using the Kaplan-Meier survival method.
Statistical analysis was performed using SPSS version
20 software (SPSS Inc., Chicago, IL) and the software
Prism (Version 7.01; GraphPad, La Jolla, CA, USA).
A p value < 0.05 was considered significant.
Results
A total of 93 two-stage septic revision hip arthroplasties
were performed from 2013 to 2015 at our institution.
Three patients died due to non-PJI-related causes. One
patient from the failure group died due to myocardial in-
farction. Two further patients died after 8 and 14
months of follow-up due to an intracerebral hemorrhage
and cardiorespiratory failure, respectively. The latter two
patients were excluded from further analysis due to
short-term follow-up. After applying the exclusion cri-
teria described above, 84 patients with hip PJI were the
subject of this study. The presumed route of infection
was perioperative in 72 and hematogenous in 12 epi-
sodes. Further demographic, clinical, and laboratory
characteristics of the cohort are summarized in Table 1.
The mean follow-up was 33.1 months (range, 24–48
months) with successful treatment of PJI.
We identified microorganisms in 73 of 84 cases (88%).
The most common isolated microorganism was
coagulase-negative staphylococci (CNS) followed by
Staphylococcus aureus and Propionibacterium (Table 2).
Thirteen patients (16%) underwent at least one revi-
sion surgery during the prosthesis-free interval due to
persistent infection, which was performed once in eight
episodes, twice in one episode, three times in two
episodes, four times in one episode, and six times in
another episode.
The mean time interval between stages was 8.7 weeks
(range, 1–25 weeks). 21.4% of the patients (18 of 84)
underwent a reimplantation after a short interval (< 6
weeks). 21.4% of patients (18 of 84) had a positive cul-
ture at the time of reimplantation, and six of these 18
patients (33.3%) with a positive culture at reimplantation
underwent a two-stage exchange after a short interval of
< 6 weeks. The same microorganism was isolated at
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reimplantation as the initially isolated microorganism in 7
of these 18 patients (39%). The Kaplan-Meier-estimated
infection-free survival after 3 years was 89.3% (95% CI,
80% to 94%) with 30 patients at risk. The survivorship of
these patients is illustrated in Fig. 1.
Interestingly, the microorganisms causing reinfection
were in none of the nine failures, the same as isolated
initially or at the time of reimplantation. The microbiol-
ogy results of explantation, reimplantation, and reinfec-
tion are summarized in Table 2.
Six of 9 failures were early failures within 4 weeks after
reimplantation and underwent an irrigation and debride-
ment followed by a 12-week course of antimicrobial
treatment. One patient had a reinfection with Candida
spp. and underwent a two-stage revision with long-term
antimicrobial suppression. One patient had a resection
arthroplasty and did not get reimplanted due to
low-demand and critical health status. Another patient
underwent a further two-stage revision, which failed
again, so a reimplantation was not performed due to
high risk of reinfection.
There were no statistical differences in infect eradica-
tion rate among the dichotomized groups (Table 3).
Discussion
Although two-stage exchange arthroplasty is being prac-
ticed for more than 20 years in treatment of PJI, results
remain unpredictable due to the lack of established
standardization, and success rates in the literature are
reported to be between 76 and 100% [5–8, 26–29] with
varied definition of failure (Table 4). The lack of consen-
sus regarding what constitutes a successful treatment for
PJI makes it difficult to compare the results of many
studies. Furthermore, the retrospective design and in-
cluding patients without standardized antimicrobial and
Table 1 Patient demographic, clinical, and outcome characteristics
Variable Hip PJI, n = 84
Age, years∗ 70 ± 9
CCI (age-adjusted)∗ 4 ± 1.9
Previous septic revision⧫ 39 (46)
1 septic revision 17
2 septic revisions 8
> 2 septic revisions 14






Time to reimplantation (day)∗ 61 ± 29.8
Short (< 6 weeks)⧫ 18 (21)
Long (> 6 weeks)⧫ 66 (79)
Surgery in prosthesis-free interval⧫ 13 (16)
Total duration of antibiotic therapy (days)∗ 116 ± 35.1
Total length of hospital stay (days)∗ 33.8 ± 17.5
Positive microbiology at reimplantation⧫ 18 (21)
CRP at reimplantation (mg/l)∗ 13.6 ± 14.9
Treatment failure⧫ 9 (11.7)
∗The values are given as the mean and the standard deviation
⧫The values are given as the number with the percentage of the group
in parentheses
Table 2 Microbiology at explantation, reimplantation, and
reinfection
Microorganism No. (%)
Explantation, n = 84 CNS 52 (62)
S. aureus 13 (15)
Propionibacterium 13 (15)
Enterococcus spp. 11 (13)
Streptococcus spp. 5 (6)
Gram-negative 3 (4)
Others 13 (15)
Reimplantation, n = 18 CNS 14 (78)




Reinfection, n = 9 Negative 3 (33)
Klebsiella pneumoniae 2 (22)
Escherichia coli 1 (11)
Staphylococcus capitis 1 (11)
Candida spp. 1 (11)
Enterobacter cloacae 1 (11)
Fig. 1 Kaplan-Meier survivorship graph showing the infection-free
survival of 84 hip PJI patients. The dotted lines represent the 95%
confidence intervals
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surgical treatment algorithm causes inhomogeneous
study cohorts, which are difficult to compare [8, 10,
30–32]. Our study was specifically designed to evalu-
ate the infect eradication outcome in an antimicro-
bially and surgically homogenously treated cohort
with a strict definition of treatment failure. In
addition, previous septic revision and multiresistant
microorganisms were not set as exclusion criteria.
Some studies [6, 10, 28] set these characteristics as
exclusion criteria, as prior revisions and multiresis-
tancy were reported to be associated with worse out-
comes [29, 33]. This was not confirmed using our
treatment algorithm. Despite this, our outcome results
in a patient cohort where almost every second a pa-
tient had a previous septic failure surgery were com-
parable with the current literature.
A potential disadvantage of two-stage exchange
arthroplasty is the high reported mortality. Ibrahim et al.
[6] showed, despite a high rate of infect eradication, a
mortality rate of 15% (19 patients), which was also con-
firmed by Berend et al. [30]. Gomez et al. [10] suggested
that the success of two-stage revision arthroplasty be
considered from the point of explantation rather than
the following reimplantation to account for failures.
Lange et al. [26] also showed in his study that only 63%
of his study cohort (82 of 130 hips) was reimplanted. Pa-
tients reimplanted were younger and had lower CCI and
a 68% lower mortality risk in the follow-up period. Un-
like the previous studies, we could perform reimplanta-
tion in all of our patients, but one (not involved in the
cohort of 93 patients), and only three out of 93 patients
died of causes unrelated to PJI after reimplantation in
our short-term follow-up. It is well known that higher
CCI and patients with previous septic revisions with
subsequent failure combined with insufficient antimicro-
bial treatment are associated with a higher risk of re-
infection and mortality, so, we propose that medical
optimization of these patients through a multidisciplin-
ary team prior two-stage revision plays a crucial role in
reducing the mortality and failure rate [34].
Our results showed similar eradication rates in epi-
sodes infected by DTT microorganisms compared to the
rest of the cohort. With a long interval as proposed by
Zimmerli et al. [22], we achieved good eradication rates,
despite the unavailability of an antibiofilm-active agent.
In our algorithm, we always treat these microorganisms
with a long interval. Furthermore, in individual cases, a
long-term suppression therapy can also contribute in re-
ducing the risk of a recurrent infection.
Positive culture during reimplantation was evident in
18 cases without any significantly higher risk for subse-
quent failure compared to the culture-negative group.
Table 3 Dichotomized data for the 84 patients
Dichotomized groups Numbers Failure p value
Previous septic revision 0.29
≥ 1 39 6
0 45 3
DTT 18 3 0.4
Non-DTT 66 6
Duration of prosthesis-free interval 0.2
Short (< 6 weeks) 18 0




Microbiology at reimplantation 0.4
Positive 18 3
Negative 66 6
Table 4 Reported rates of infection eradication in literature with two-stage exchange
Study Number of patients Period of study Definition of failure Rate of infection eradication (%)
Chen et al. [5] 155 hips 2001–2010 Repeated operation
Long-term antibiotics
91.7
Oussedik et al. [7] 39 hips 1999–2002 Recurrent infection 96
Tan et al. [8] 186 knees
81 hips
1999–2013 Delphi-based definition [17] 76









Fink et al. [28] 36 hips 2002–2006 Clinical signs of infection
CRP more than 10 mg/dl
Osteolysis
100
Berend et al. [30] 186 hips 1996–2009 Further surgery for infection 83
Ibrahim et al. [6] 125 hips 2000–2008 Recurrence of infection
Leung et al. [48] 50 hips 1998–2006 Recurrence of infection 79
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We were recently able to show in a cohort of patients
with hip and knee PJI (same hip patient cohort used also
in this study) that positive culture at reimplantation was
independently associated with two times the risk of sub-
sequent failure [16]. Possible reasons for lacking signifi-
cance in this study could be the lower number of
patients, significantly higher rate of failure in PJI involv-
ing the knee joint, short follow-up, and differences in
used statistical methods (multivariate regression analysis
vs. Fisher exact test). Tan et al. identified also recently
that the risk of treatment failure was significantly higher
and reinfection occurred earlier for the cases with a
positive culture at reimplantation [8]. Unlike these stud-
ies, previous studies could not show any association be-
tween positive culture and worse outcomes [11, 35, 36].
But this seems to be due to the small sample size of
these studies. Differently, in our study than in other
studies, patients with a relevant culture at reimplanta-
tion were administered a prolonged antimicrobial treat-
ment, which could have prevented some failures. Also,
in a randomized controlled trial, it was shown that the
addition of 3 months of oral antibiotics appeared to im-
prove infection-free survival at short-term follow-up
[37]. We recommend, therefore, to always implement an
antimicrobial treatment after reimplantation, if possible
with antibiofilm-active agents, and treating physicians
should be aware of possible worse outcomes associated
with positive cultures at reimplantation.
Despite suggestions from many authors, to apply a
prosthesis free interval of 2–8 weeks followed by an anti-
biotic holiday of 2 weeks and preoperative aspiration be-
fore proceeding to second stage [4, 38, 39], we postulate
that a short interval could be as effective in PJI eradica-
tion as the long interval in selected patients. The key to
success when using short intervals seems to be the avail-
ability of an antibiofilm-active agent. None of our 18 ep-
isodes treated with a short interval had a recurrence of
infection. We do not recommend waiting for CRP in
serum to be normalized and an antibiotic-free period
with joint aspiration before reimplantation, as cultures
from synovial fluid and CRP seem to be uncertain pa-
rameters to exclude persistent infection [40–42]. Wait-
ing for CRP to normalize and an antibiotic-free period
with joint aspiration prior reimplantation can delay re-
implantation unnecessary.
The implantation of a temporary antibiotic-impregnated
spacer in the interim period is used worldwide in
two-stage exchange arthroplasty, since it enables preserva-
tion of the joint space, ensures high local concentrations
of antibiotics, and the reimplantation sometimes can be
easier due to the absence of scar tissue in the acetabulum
and medullary canal [43]. Nevertheless, spacers may act as
a foreign body to which microorganisms may adhere,
grow, and maintain infection [44, 45]. Several studies
identified biofilm formation on the sonicated spacers and
reported the association between an infection of the ce-
ment spacer and poor clinical outcome and significantly
higher failure and reinfection rate after two-stage ex-
change arthroplasty [44–46]. Furthermore, in a compari-
son study from Marczak et al., the reinfection rate was
similar in patients with and without spacer and five pa-
tients from the spacer group underwent spacer exchange
due to recurrence of infection [43]. Additionally, several
mechanical complications may occur when cement
spacers are used, such as spacer fractures, dislocations,
and femoral fractures. In our hands, resection arthroplasty
has an important role in two-stage exchange arthroplasty
with similar success rates in terms of infection control and
should be considered especially in cases treated with
shorter intervals and when complications related to
spacers are expected.
Our study has some limitations. It is not a controlled
but an observational study and all cases were from one
single center. The mean follow-up time of 2 years is con-
sidered to be only a short time [17], and a longer
follow-up is needed not to miss a possible relapse after a
few years. Another limitation includes the relatively
small sample size of our study despite the sample being
large for a single center over 3 years, so the missing sig-
nificance between dichotomized groups could be attrib-
uted to this limitation.
Conclusion
In conclusion, with a standardized therapeutic algorithm
using a two-stage exchange arthroplasty, high infect
eradication rates were achieved, irrespective of risk fac-
tors predictive of failure. A multidisciplinary team
should review each patient and compose an individual-
ized treatment plan based on a strict algorithm.
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